Search results

599 results

Sorted by Relevance . Sort by Date

  1. Liver cancers

    Everything NICE has said on liver and bile duct cancers in an interactive flowchart

  2. Sarcoma

    Everything NICE has said on sarcoma in an interactive flowchart

  3. Brain tumours and metastases

    Everything NICE has said on brain tumours in adults, including cancer, in an interactive flowchart

  4. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  5. Ovarian cancer

    Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart

  6. Prostate cancer

    Everything NICE has said on diagnosing and treating prostate cancer in an interactive flowchart

  7. Melanoma

    Everything NICE has said assessing and managing melanoma in an interactive flowchart

  8. Lung cancer

    Everything NICE has said on diagnosing and treating lung cancer in an interactive flowchart

  9. Renal cancer

    Everything NICE has said on renal (kidney) cancer in an interactive flowchart

  10. Bladder cancer

    Everything NICE has said on bladder cancer in adults in an interactive flowchart

  11. Advanced breast cancer

    Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

  12. Upper aerodigestive tract cancer

    Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart

  13. Oesophageal and gastric cancer

    Everything NICE has said on assessing and managing non-stromal oesophageal and gastric cancer in adults

  14. Skin cancer

    Everything NICE has said on skin cancers, including melanoma, basal cell carcinoma and squamous cell carcinoma in an interactive flowchart

  15. Neutropenic sepsis

    Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart

  16. Myeloma

    Everything NICE has said on diagnosing and managing myeloma, and preventing and managing its complications in an interactive flowchart

  17. Blood and bone marrow cancers

    Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

  18. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  19. Skin conditions

    Everything NICE has said on managing skin conditions and skin damage in an interactive flowchart

  20. Dementia

    Everything NICE has said on assessment, management and support for people living with dementia and Alzheimer's disease and their carers in an interactive flowchart

  21. Colorectal cancer

    Everything NICE has said on diagnosing and managing colorectal (bowel) cancer in an interactive flowchart

  22. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

  23. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

  24. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

  25. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  26. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  27. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  28. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

  29. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

  30. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal

  31. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  32. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

  33. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

  34. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  35. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

    Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C

  36. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)

    Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures